Fibrosis: Oncodesign and TiumBio sign collaboration agreement for R&D of drug candidates
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix® drug candidates and their early-stage analysis, while TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates. This initial phase of the collaboration will be funded by TiumBio.
Outsourcing drug discovery has become an overwhelmingly accepted approaches across the pharmaceutical industry from virtual biotech to large pharmaceutical companies as part of the globalization process. It does represent a cost-effective opportunity to access specialized technologies and expert scientist resources having a broad knowledge of pharmaceutical drug discovery development. Oncodesign’s objective with DRIVE™ offer is to provide its customers with the best possible options and state-of-the-art technologies to progress their drug discovery in the shortest possible time with the highest quality. Oncodesign is doing so by setting up under a single leadership, privileged partnering with selected and trusted companies sharing the same values of innovation and quality as its own. Hits finding and validation are important phases in early drug discovery. With Program, Oncodesign is providing DNA encoded libraries, fragments screening along with Hit validation using NanoDSF, MST, SPR, ITC and Structural Biology (Cryo-EM and X-Ray crystallography) supported by artificial intelligence.
Key learning objectives
Introduction to a solution provider from hits finding to IND filing
Advantages of drug discovery integrated provider vs silos approach
Special focus on Hit identification and validation across DNA encoded libraries, Artificial Intelligence, Biophsysics and Biostructures